The combinatorial effect of AZD4547/BI2536 in KRAS‐mutant lung and pancreatic cancer cells was confirmed by clonogenic and apoptotic assay, where the drug combination markedly enhanced growth inhibition and led to a significantly greater percentage of apoptotic cells than single agents (Fig 2C and D), which did not occur in SW620, DLD‐1, or EBC‐1 cells (Appendix Fig S2D). Here, KRAS is linked to familial pancreatic carcinoma.